Skip to main content
. 2017 Jun 22;12(6):e0179680. doi: 10.1371/journal.pone.0179680

Fig 2. Absolute risk for HBV reactivation in HBsAg-positive lung cancer patients without(2A) or with (2B) antiviral prophylaxis.

Fig 2